NYSE:BIO

Bio-Rad Laboratories (BIO) Stock Forecast, Price & News

$352.47

+2.22 (+0.63%)

(As of 09/27/2023 ET)

Compare

Today's Range: $351.39
▼
$354.70
50-Day Range: $350.25
▼
$422.63
52-Week Range: $344.63
▼
$509.62

Volume: 109,365 shs
Average Volume: 188,290 shs
Market Capitalization: $10.25 billion

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $533.00

Bio-Rad Laboratories MarketRank™ Forecast

Analyst Rating: Buy
3.00 Rating Score
Upside/Downside: 51.2% Upside
$533.00 Price Target
Short Interest: Healthy
1.90% of Float Sold Short
Dividend Strength: N/A
Sustainability: -1.54
Upright™ Environmental Score
News Sentiment: 0.33
Based on 16 Articles This Week
Insider Trading: Selling Shares
$1.05 M Sold Last Quarter
Proj. Earnings Growth: 14.31%
From $12.93 to $14.78 Per Share

Overall MarketRank^™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.79 out of 5 stars

Medical Sector

72nd out of 976 stocks

Analytical Instruments Industry

6th out of 27 stocks

3.5

Analyst's Opinion

Consensus Rating
Bio-Rad Laboratories has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $533.00, Bio-Rad Laboratories has a forecasted upside of 51.2% from its current price of $352.47.
Amount of Analyst Coverage
Bio-Rad Laboratories has only been the subject of 3 research reports in the past 90 days.

5.0

Short Interest

Percentage of Shares Shorted
1.90% of the float of Bio-Rad Laboratories has been sold short.
Short Interest Ratio / Days to Cover
Bio-Rad Laboratories has a short interest ratio ("days to cover") of 2.1, which is generally considered an acceptable ratio of short interest to trading volume.
Change versus previous month
Short interest in Bio-Rad Laboratories has recently decreased by 10.71%, indicating that investor sentiment is improving significantly.

0.0

Dividend Strength

Dividend Yield
Bio-Rad Laboratories does not currently pay a dividend.
Dividend Growth
Bio-Rad Laboratories does not have a long track record of dividend growth.

4.2

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
Bio-Rad Laboratories has received a 60.92% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Biochemical assay kits", "PCR machines", "Laboratory reagents", and "Protein gels" products. See details.
Environmental Sustainability
The Environmental Impact score for Bio-Rad Laboratories is -1.54.

2.4

News and Social Media Coverage

News Sentiment
Bio-Rad Laboratories has a news sentiment score of 0.33. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.73 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 16 news articles for Bio-Rad Laboratories this week, compared to 8 articles on an average week.
Search Interest
Only 11 people have searched for BIO on MarketBeat in the last 30 days. This is a decrease of -21% compared to the previous 30 days.
MarketBeat Follows
3 people have added Bio-Rad Laboratories to their MarketBeat watchlist in the last 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bio-Rad Laboratories insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $1,045,067.00 in company stock.
Percentage Held by Insiders
17.06% of the stock of Bio-Rad Laboratories is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
63.98% of the stock of Bio-Rad Laboratories is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

1.3

Earnings and Valuation

Earnings Growth
Earnings for Bio-Rad Laboratories are expected to grow by 14.31% in the coming year, from $12.93 to $14.78 per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bio-Rad Laboratories is -23.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bio-Rad Laboratories is -23.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bio-Rad Laboratories has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

About Bio-Rad Laboratories (NYSE:BIO) Stock

Bio-Rad Laboratories, Inc. manufactures, and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. The company operates through Life Science and Clinical Diagnostics segments. The Life Science segment develops, manufactures, and markets reagents, apparatus, and laboratory instruments that are used in research techniques, biopharmaceutical production processes, and food testing regimes. It focuses on selected segments of the life sciences market in proteomics, genomics, biopharmaceutical production, cellular biology, and food safety. This segment serves universities and medical schools, industrial research organizations, government agencies, pharmaceutical manufacturers, biotechnology researchers, food producers, and food testing laboratories. The Clinical Diagnostics segment designs, manufactures, sells, and supports test systems, informatics systems, test kits, and specialized quality controls for clinical laboratories in the diagnostics market. This segment offers reagents, instruments, and software, which address specific niches within the in vitro diagnostics test market. It sells its products to reference laboratories, hospital laboratories, state newborn screening facilities, physicians' office laboratories, and transfusion laboratories. In addition, the company offers products and systems to separate complex chemical and biological materials, as well as to identify, analyze, and purify components. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.

BIO Price History

30 days | 90 days | 365 days | Advanced Chart

BIO Stock News Headlines

September 23, 2023 | americanbankingnews.com

Bio-Rad Laboratories, Inc. (NYSE:BIO) to Post Q2 2025 Earnings of $4.10 Per Share, Zacks Research Forecasts

September 22, 2023 | americanbankingnews.com

Zacks Research Comments on Bio-Rad Laboratories, Inc.'s Q3 2023 Earnings (NYSE:BIO)

September 28, 2023 | Behind the Markets (Ad)

The single greatest medical breakthrough of all time?

We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.

September 19, 2023 | msn.com

How California can improve safety and transparency of privately run bio labs

September 14, 2023 | benzinga.com

Global Laboratory Disposable Market Size to Forecasted to Surge $18 Billion Growth by 2030, Exhibit a CAGR of 3.2%

September 8, 2023 | finance.yahoo.com

Unveiling Bio-Rad Laboratories (BIO)'s Value: Is It Really Priced Right? A Comprehensive Guide

September 6, 2023 | finance.yahoo.com

Global Reporter Gene Assay Market Report 2023: Key Players include Abcam, Bio-Rad, Merck, Thermo Fisher, Danaher, Promega and Genecopoeia

August 28, 2023 | finance.yahoo.com

Bio-Rad to Participate in Fireside Chat During Wells Fargo’s 2023 Healthcare Conference

September 28, 2023 | Chaikin Analytics (Ad)

His system isolated NVIDIA - Here's His Next Buy.

Most investors don't know the truth about A.I. 50-year Wall Street Insider Marc Chaikin reveals what you should be doing to profit. Learn more here.

August 22, 2023 | finance.yahoo.com

The global flow cytometry market is projected to reach USD 7.0 billion by 2028 from USD 4.7 billion in 2023, at a CAGR of 8.3%

August 14, 2023 | finance.yahoo.com

Mason Hawkins' Q2 2023 13F Filing Update: Top Trades and Portfolio Overview

August 3, 2023 | finance.yahoo.com

Bio-Rad Reports Second-Quarter 2023 Financial Results

August 3, 2023 | finance.yahoo.com

Bio-Rad Laboratories (BIO) Tops Q2 Earnings Estimates

July 25, 2023 | finance.yahoo.com

Bio-Rad Laboratories (BIO) to Post Q2 Earnings: What Awaits?

July 24, 2023 | gurufocus.com

Is Bio-Rad Laboratories (BIO) Significantly Undervalued? A Comprehensive GF Value Analysis

July 22, 2023 | gurufocus.com

Is Bio-Rad Laboratories Inc (BIO) Undervalued? An In-Depth Look at Its GF Value

July 21, 2023 | marketwatch.com

Evelo Shares Surge 20% After Terminating Sublease

July 11, 2023 | fool.com

Bio-Rad Laboratories (NYSE: BIO.B)

July 11, 2023 | finance.yahoo.com

Are Options Traders Betting on a Big Move in Bio-Rad Laboratories (BIO) Stock?

June 27, 2023 | stocknews.com

Are These 3 Medical Stocks Worth Buying?

June 23, 2023 | benzinga.com

Global Cardiac Marker Market Report 2023: Rising Prevalence of Cardiac Diseases Fuels the Sector

June 22, 2023 | marketwatch.com

Cloud ERP Market Share, Industry Size, Growth, Opportunities and Forecast to 2030 | ALS, Bio-Rad Laboratories, Bureau Veritas SA, Campden BRI

June 2, 2023 | finance.yahoo.com

Bio-Rad Laboratories (BIO) Gains But Lags Market: What You Should Know

June 1, 2023 | finance.yahoo.com

Bio-Rad to Present Company Overview at Jefferies Healthcare Conference

May 31, 2023 | finance.yahoo.com

Is It Time To Consider Buying Bio-Rad Laboratories, Inc. (NYSE:BIO)?

May 17, 2023 | marketwatch.com

Automated Blood Bank System Market Projected to Show Strong Growth by 2030| Grifols, Bio-Rad Laboratories, Inc, Immucor

May 16, 2023 | marketwatch.com

Label Free Detection Market Outlook 2023 and Forecast to 2030 | Ametek, Bio-Rad Laboratories, General Electric

See More Headlines

Receive BIO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bio-Rad Laboratories and its competitors with MarketBeat's FREE daily newsletter.

BIO Company Calendar

Last Earnings: 8/03/2023
Today: 9/28/2023
Next Earnings (Estimated): 10/26/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Analytical instruments
Sub-Industry: Life Sciences Tools & Services
Sector: Medical
Current Symbol: NYSE:BIO
CUSIP: 09057220
CIK: 12208
Web: www.bio-rad.com
Phone: (510) 724-7000
Fax: 510-741-5817
Employees: 8,200
Year Founded: 1952

Price Target and Rating

Average Stock Price Forecast: $533.00
High Stock Price Forecast: $550.00
Low Stock Price Forecast: $524.00
Forecasted Upside/Downside: +51.2%
Consensus Rating: Buy
Rating Score (0-4): 3.00
Research Coverage: 3 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($15.01)
Trailing P/E Ratio: N/A
Forward P/E Ratio: 27.26
P/E Growth: N/A
Net Income: $-3,627,530,000.00
Net Margins: -15.52%
Pretax Margin: -19.20%
Return on Equity: 4.02%
Return on Assets: 2.85%

Debt

Debt-to-Equity Ratio: 0.14
Current Ratio: 5.39
Quick Ratio: 4.06

Sales & Book Value

Annual Sales: $2.80 billion
Price / Sales: 3.66
Cash Flow: $14.59 per share
Price / Cash Flow: 24.16
Book Value: $324.89 per share
Price / Book: 1.08

Miscellaneous

Outstanding Shares: 29,080,000
Free Float: 24,116,000
Market Cap: $10.25 billion
Optionable: Optionable
Beta: 0.89

Social Links

A Guide To High-Short-Interest Stocks

MarketBeat's analysts have just released their top five short plays for October 2023. Learn which stocks have the most short interest and how to trade them. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

Mr. Norman D. Schwartz (Age 73)
Chairman, CEO & Pres
Comp: $2.13M

Mr. Ilan Daskal (Age 57)
Exec. VP & CFO
Comp: $952.43k

Dr. Andrew J. Last Ph.D. (Age 63)
Exec. VP & COO
Comp: $1.12M

Dr. Simon May
Exec. VP & Pres of the Life Science Group

Ms. Dara Grantham Wright (Age 47)
Exec. VP & Pres of Clinical Diagnostics Group
Comp: $849.53k

Mr. Ajit Ramalingam (Age 50)
Sr. VP & Chief Accounting Officer

Mr. Yong Chung
VP of Investor Relations

Mr. Timothy S. Ernst (Age 63)
Exec. VP, Gen. Counsel & Sec.

Matthew Werner
Sr. VP and Chief Compliance & Privacy Officer

Colleen Corey
Exec. VP of Global HR

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BIO Stock - Frequently Asked Questions

Should I buy or sell Bio-Rad Laboratories stock right now?: 3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Bio-Rad Laboratories in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" BIO shares.
View BIO analyst ratings or view top-rated stocks.
What is Bio-Rad Laboratories' stock price forecast for 2023?: 3 Wall Street research analysts have issued 1-year target prices for Bio-Rad Laboratories' stock. Their BIO share price forecasts range from $524.00 to $550.00. On average, they predict the company's share price to reach $533.00 in the next year. This suggests a possible upside of 51.2% from the stock's current price.
View analysts price targets for BIO or view top-rated stocks among Wall Street analysts.
How have BIO shares performed in 2023?: Bio-Rad Laboratories' stock was trading at $420.49 on January 1st, 2023. Since then, BIO shares have decreased by 16.2% and is now trading at $352.47.
View the best growth stocks for 2023 here.
Are investors shorting Bio-Rad Laboratories?: Bio-Rad Laboratories saw a decline in short interest in September. As of September 15th, there was short interest totaling 388,500 shares, a decline of 10.7% from the August 31st total of 435,100 shares. Based on an average trading volume of 189,000 shares, the days-to-cover ratio is presently 2.1 days. Currently, 1.9% of the shares of the company are sold short.
View Bio-Rad Laboratories' Short Interest.
When is Bio-Rad Laboratories' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, October 26th 2023.
View our BIO earnings forecast.
How were Bio-Rad Laboratories' earnings last quarter?: Bio-Rad Laboratories, Inc. (NYSE:BIO) announced its quarterly earnings results on Thursday, August, 3rd. The medical research company reported $3.00 EPS for the quarter, topping the consensus estimate of $2.55 by $0.45. The medical research company earned $681.10 million during the quarter, compared to the consensus estimate of $697.96 million. Bio-Rad Laboratories had a negative net margin of 15.52% and a positive trailing twelve-month return on equity of 4.02%. The business's quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter in the prior year, the company posted $3.38 earnings per share.
Read the conference call transcript.
What ETFs hold Bio-Rad Laboratories' stock?: ETFs with the largest weight of Bio-Rad Laboratories (NYSE:BIO) stock in their portfolio include ETFMG Treatments Testing and Advancements ETF (GERM), Harbor Health Care ETF (MEDI), Putnam BioRevolution ETF (SYNB), Principal Healthcare Innovators ETF (BTEC), Invesco S&P 500 Equal Weight Health Care ETF (RYH), Invesco S&P 500 Equal Weight Health Care ETF (RSPH), ROBO Global Healthcare Technology and Innovation ETF (HTEC) and First Trust Indxx Medical Devices ETF (MDEV).
What guidance has Bio-Rad Laboratories issued on next quarter's earnings?: Bio-Rad Laboratories updated its FY 2023 earnings guidance on Thursday, August, 3rd. The company provided EPS guidance of for the period. The company issued revenue guidance of $2.82 billion-$2.82 billion, compared to the consensus revenue estimate of $2.90 billion.

What is Norman Schwartz's approval rating as Bio-Rad Laboratories' CEO?: 325 employees have rated Bio-Rad Laboratories Chief Executive Officer Norman Schwartz on Glassdoor.com. Norman Schwartz has an approval rating of 84% among the company's employees.
What other stocks do shareholders of Bio-Rad Laboratories own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bio-Rad Laboratories investors own include BioMarin Pharmaceutical (BMRN), Incyte (INCY), Puma Biotechnology (PBYI), AbbVie (ABBV), NVIDIA (NVDA), Broadcom (AVGO), Johnson & Johnson (JNJ), Advanced Micro Devices (AMD), Alibaba Group (BABA) and Intel (INTC).
What is Bio-Rad Laboratories' stock symbol?: Bio-Rad Laboratories trades on the New York Stock Exchange (NYSE) under the ticker symbol "BIO."
Who are Bio-Rad Laboratories' major shareholders?: Bio-Rad Laboratories' stock is owned by many different retail and institutional investors. Top institutional shareholders include BlackRock Inc. (5.33%), Veritas Asset Management LLP (3.84%), Veritas Asset Management LLP (3.91%), Brown Advisory Inc. (3.13%), State Street Corp (3.10%) and Alliancebernstein L.P. (1.58%). Insiders that own company stock include Ajit Ramalingam, Annette Tumolo, Ilan Daskal, Michael Crowley, Timothy S Ernst and Timothy S Ernst.
View institutional ownership trends.
How do I buy shares of Bio-Rad Laboratories?: Shares of BIO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Bio-Rad Laboratories' stock price today?: One share of BIO stock can currently be purchased for approximately $352.47.
How much money does Bio-Rad Laboratories make?: Bio-Rad Laboratories (NYSE:BIO) has a market capitalization of $10.25 billion and generates $2.80 billion in revenue each year. The medical research company earns $-3,627,530,000.00 in net income (profit) each year or ($15.01) on an earnings per share basis.
How many employees does Bio-Rad Laboratories have?: The company employs 8,200 workers across the globe.
Does Bio-Rad Laboratories have any subsidiaries?: The following companies are subsidiares of Bio-Rad Laboratories: (f/k/a Bio-Rad Laboratories (Israel) Inc.), BIO-RAD spol. s r.o., Bio-Metrics (U.K.) Limited, Bio-Rad, Bio-Rad (Shanghai) Life Science Research & Development Co. Ltd., Bio-Rad 1, Bio-Rad AbD Serotec GmbH, Bio-Rad AbD Serotec Ltd, Bio-Rad China Ltd., Bio-Rad Denmark ApS, Bio-Rad Europe GmbH, Bio-Rad Export LLC, Bio-Rad Finland Oy (f/k/a DiaMed Fennica Oy), Bio-Rad France, Bio-Rad France Holding, Bio-Rad Germany Holding GmbH, Bio-Rad Haifa Ltd., Bio-Rad Holdings LLC, Bio-Rad Hungary Trading LLC, Bio-Rad IHC Europe GmbH, Bio-Rad Innovations, Bio-Rad Korea Ltd., Bio-Rad Laboratories (Canada) Limited, Bio-Rad Laboratories (India) Private Limited, Bio-Rad Laboratories (Pty) Ltd, Bio-Rad Laboratories (Rishon) Inc., Bio-Rad Laboratories (Shanghai) Co. Ltd., Bio-Rad Laboratories (Singapore) Pte Ltd, Bio-Rad Laboratories AB, Bio-Rad Laboratories AG, Bio-Rad Laboratories B.V., Bio-Rad Laboratories Ges.m.b.H., Bio-Rad Laboratories GmbH, Bio-Rad Laboratories K.K., Bio-Rad Laboratories Limited, Bio-Rad Laboratories Logistik GmbH, Bio-Rad Laboratories Ltd., Bio-Rad Laboratories M.EPE, Bio-Rad Laboratories NV, Bio-Rad Laboratories Pty Ltd, Bio-Rad Laboratories S.A., Bio-Rad Laboratories S.r.l., Bio-Rad Laboratories SAS, Bio-Rad Laboratories-Aparelhos e Reagentes para Laboratórios Lda, Bio-Rad Laboratorii OOO, Bio-Rad Laboratórios Brasil Ltda., Bio-Rad Luxembourg S.à r.l., Bio-Rad Medical Diagnostics GmbH, Bio-Rad Middle East FZ-LLC, Bio-Rad Norway AS, Bio-Rad Pacific Limited, Bio-Rad Pasteur, Bio-Rad Polska Sp. z o.o., Bio-Rad QL Inc., Bio-Rad S.A., Bio-Rad Services France, Bio-Rad Services UK Limited, Biotest - Businesses, Blackhawk Biosystems, Bridger Technologies Inc., Celsee, Ciphergen Biosystems - ProteinChip Systems Business, DiaMed (G.B.) Ltd, DiaMed (Schweiz) GmbH, DiaMed Benelux NV, DiaMed Diagnostika Deutschland GmbH, DiaMed France SA, DiaMed GmbH, DiaMed Holding AG, DiaMed Holding GmbH, DiaMed Latino-América S.A., DiaMed S.E.A. Limited, DiaMed Österreich GmbH, Distribudora de Analítica para la Medicina Ibérica S.A.U., Dropworks Inc., GnuBIO Inc., Helix Diagnostics, IMV Medical Information Division Inc., International Marketing Ventures Ltd., MJ GeneWorks, Propel Labs - Cell Sorting System Division, QuantaLife, Quantase Ltd., Raindance Technologies Limited, Raindance Techologies Inc., Research Specialties for Laboratories NV, Respiratory Diagnostics Inc., and Wuxi BioCanal Nano Technology Co. Ltd..
Read More
How can I contact Bio-Rad Laboratories?: Bio-Rad Laboratories' mailing address is 1000 ALFRED NOBEL DRIVE, HERCULES CA, 94547. The official website for the company is www.bio-rad.com. The medical research company can be reached via phone at (510) 724-7000, via email at investor_relations@bio-rad.com, or via fax at 510-741-5817.

This page (NYSE:BIO) was last updated on 9/28/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial